Claudia Piombino

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2026

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 23, 2025

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study.

Journal: Familial cancer

Published: December 15, 2025

Future directions for antibody-drug conjugates in urothelial cancer.

Journal: Expert review of anticancer therapy

Published: November 20, 2025

Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndrome.

Journal: Menopause (New York, N.Y.)

Published: November 18, 2025

Molecular Landscape of Advanced Endometrial Cancer: Exploratory Analyses at Modena Cancer Center (MEMO).

Journal: International journal of molecular sciences

Published: November 11, 2025

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Journal: The oncologist

Published: June 13, 2025

Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study.

Journal: NPJ breast cancer

Published: February 09, 2025

Chemoprevention strategies in hereditary breast and ovarian cancer syndromes.

Journal: Tumori

Published: November 21, 2024

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Journal: Breast (Edinburgh, Scotland)

Published: October 22, 2024

New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives.

Journal: International journal of molecular sciences

Published: August 07, 2024

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Journal: NPJ breast cancer

Published: August 02, 2024

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study.

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study.

Future directions for antibody-drug conjugates in urothelial cancer.

Future directions for antibody-drug conjugates in urothelial cancer.

Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndrome.

Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndrome.

Molecular Landscape of Advanced Endometrial Cancer: Exploratory Analyses at Modena Cancer Center (MEMO).

Molecular Landscape of Advanced Endometrial Cancer: Exploratory Analyses at Modena Cancer Center (MEMO).

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study.

Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study.

Chemoprevention strategies in hereditary breast and ovarian cancer syndromes.

Chemoprevention strategies in hereditary breast and ovarian cancer syndromes.

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives.

New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives.

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.